预约演示
更新于：2025-08-19
Metformin Hydrochloride
盐酸二甲双胍
更新于：2025-08-19
概要
基本信息
简介盐酸二甲双胍，商品名为GLUCOPHAGE，用于治疗2型糖尿病。它于1957年在法国首次获批，现在由Bristol Myers Squibb公司生产。GLUCOPHAGE通过激活PRKAB1，帮助改善10岁及以上成人和儿童患者的血糖控制，配合饮食和运动使用。该药物属于双胍类药物，通常用作辅助疗法，帮助管理2型糖尿病患者的血糖水平。 |
药物类型 小分子化药 |
别名 Meiformin Hydrochloride、Metformin hydrochloride (JP17/USP)、Metformin Hydrochlorride + [67] |
靶点 |
作用方式 激活剂 |
作用机制 PRKAB1激活剂(腺苷酸活化蛋白激酶亚基β1激活剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 中国 (1992-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C4H12ClN5 |
InChIKeyOETHQSJEHLVLGH-UHFFFAOYSA-N |
CAS号1115-70-4 |
关联
2,479
项与 盐酸二甲双胍 相关的临床试验NCT07057479
Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With Metformin
NCT05910554
Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial
CTRI/2024/10/074853
Efficacy and safety of Curcuma longa either alone or in combination with metformin on glycemic status in prediabetes population: A Randomized, double-blinded, double-dummy, placebo-controlled, factorial design trial - NIL
100 项与 盐酸二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 盐酸二甲双胍 相关的专利（医药）
登录后查看更多信息
22,282
项与 盐酸二甲双胍 相关的文献（医药）2025-12-25Oriental Journal of Chemistry
Quantitative UV-Spectrophotometric Method for the Analysis of Teneligliptin HBr and Metformin HCl in Pharmaceutical Dosage form: Development and Validation
作者: Gahtori, Archana ; Khanduri, Praveen
This study developed a UV-spectrophotometric method for the simultaneous quantification of Metformin HCl and Teneligliptin HBr. Both active pharmaceutical ingredients were found to be soluble in 0.1N sulfuric acid, which was thus chosen as the solvent for analysis. The maximum absorption wavelengths for Metformin HCl and Teneligliptin HBr were identified at 220 nm and 240 nm, respectively. Standard stock solutions were prepared, and samples from commercially available tablets were accurately measured and dissolved for testing. Method validation included evaluations of linearity, precision (intra-day and inter-day), accuracy, robustness, as well as detection (LOD) and quantification limits (LOQ). The method exhibited strong precision and accuracy, with %RSD values less than 2%. Both LOD and LOQ demonstrated sufficient sensitivity, and the method proved effective for analyzing commercial formulations, achieving compliance levels of 99.20% for Metformin and 102.00% for Teneligliptin.
2025-12-01IMMUNOLOGIC RESEARCH
Metformin suppresses gammadelta T17 cell differentiation alleviating DSS-induced colitis
Article
作者: Wang, Yungang ; Tang, Qinfang ; Zhi, Yaru ; Liu, Hongli ; Xiao, Lihua ; Shen, Langping ; Yan, Dongmei ; Cai, Aiting ; Sun, Mingzhong ; Ju, Huixiang ; Yang, Rui ; Chen, Hongmei
Ulcerative colitis (UC) is a chronic, nonspecific, relapsing inflammatory bowel disease. Metformin has pleiotropic effects including anti-inflammatory properties and a notable impact on the gut microbiome. γδT17 cells play crucial role in initiating and maintaining intestinal inflammation. The effect of metformin on γδT17 cells remains unclear. This study aims to explore the connection between metformin-mediated ameliorated response in colitis mice and γδT17 cell activity. The role of γδT17 cell inhibition in metformin-mediated colitis amelioration was evaluated in mice. The effect of metformin on γδT17 differentiation and the possible mechanism were evaluated in a set of in vitro experiments. Results showed that the accumulation of γδT17 cells was negatively correlated with metformin treatment in DSS-induced colitis mice. Exogenous γδT17 cells blocked metformin-mediated colitis inhibition. Furthermore, metformin inhibited γδT17 differentiation, which was related to the inhibition of mTOR/RORγt activity. Our results reveal that metformin ameliorates colitis symptoms by suppressing γδT17 differentiation, suggesting a viable strategy against UC, although the mechanism of metformin in inhibiting γδT17 differentiation remains to be further studied.
2025-12-01COLLOIDS AND SURFACES B-BIOINTERFACES
Poly (lactic-co-glycolic acid) (PLGA) nanoparticles for sustained release of metformin hydrochloride within cells: A therapy for Type 2 diabetes mellitus
Article
作者: Sun, Qinyu ; Li, Jianfeng ; Song, Xinzhong ; Li, Jianyong ; Zhang, Yongqi ; Ji, Maocheng ; Man, Jia
Type 2 diabetes mellitus (T2DM) is the third leading chronic disease threatening human health, with patients primarily managing their blood glucose levels through oral administration of metformin hydrochloride (MH). However, oral delivery of the pure drug faces challenges such as low bioavailability and significant gastrointestinal side effects. To address these, we employed a high-pressure homogenizer to prepare PLGA nanoparticles encapsulating the drug via a double emulsion method. Orthogonal experiments revealed that both shear pretreatment and high-pressure homogenization significantly influenced the particle properties, which were subsequently characterized. The average particle size could reach as small as 113.00 nm, with an encapsulation efficiency up to 64.69 %. The surface of these nanoparticles was negatively charged, enabling sustained drug release for 36 h in vitro. They exhibited excellent biocompatibility, maintaining a 95.74 % cell survival rate after 48 h of co-culture with hepatocytes, and were capable of being internalized by cells. In vivo experiments demonstrated that orally administered MH-PLGA nanoparticles could sustain blood glucose lowering effects for 8-10 h. Compared with traditional oral metformin hydrochloride, MH-PLGA nanoparticles offer higher bioavailability and lower gastrointestinal side effects, which are expected to bring better therapeutic effects to patients.
100 项与 盐酸二甲双胍 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糖尿病 | 美国 | 2004-04-27 | |
| 2型糖尿病 | 中国 | 1992-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 浸润性乳腺癌 | 临床3期 | 美国 | 2024-12-16 | |
| 慢性病 | 临床3期 | 美国 | 2020-07-29 | |
| 获得性免疫缺陷综合征 | 临床3期 | 美国 | 2019-02-01 | |
| 腹主动脉瘤 | 临床3期 | 奥地利 | 2018-09-26 | |
| 脆性X综合征 | 临床3期 | 美国 | 2018-04-30 | |
| 脆性X综合征 | 临床3期 | 加拿大 | 2018-04-30 | |
| 代谢综合征 | 临床3期 | 美国 | 2017-08-07 | |
| 非典型增生 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺癌 | 临床3期 | 美国 | 2015-11-23 | |
| 乳腺增生 | 临床3期 | 美国 | 2015-11-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 141 | (Metformin) | 簾網窪窪壓鬱鏇繭構築(願築獵蓋窪鑰廠鏇獵窪) = 艱廠鹹簾糧製壓顧鑰選 憲築積範糧願簾膚鬱鏇 (鹽製繭憲網衊網艱餘觸, 0.0002) 更多 | - | 2025-08-06 | ||
Placebo (Placebo) | 簾網窪窪壓鬱鏇繭構築(願築獵蓋窪鑰廠鏇獵窪) = 夢蓋獵糧襯鬱艱齋廠齋 憲築積範糧願簾膚鬱鏇 (鹽製繭憲網衊網艱餘觸, 0.0002) 更多 | ||||||
临床3期 | 3,214 | (Arm G - Metformin) | 網鬱築壓鑰鏇窪鏇蓋糧(鏇願憲齋壓遞鑰願襯齋) = 構鹹艱鹽顧繭餘網醖積 壓糧願顧鬱遞襯餘鬱餘 (壓廠構築願衊鹽衊憲糧, 網夢廠鑰蓋鏇餘膚糧範 ~ 鹹蓋選築願觸選鏇膚襯) 更多 | - | 2025-07-20 | ||
Placebo (Arm G - Placebo) | 網鬱築壓鑰鏇窪鏇蓋糧(鏇願憲齋壓遞鑰願襯齋) = 選範構淵鹽鹽衊鹽醖鬱 壓糧願顧鬱遞襯餘鬱餘 (壓廠構築願衊鹽衊憲糧, 築衊鏇繭製選獵憲襯襯 ~ 鹹鏇齋簾艱鬱觸網鏇鑰) 更多 | ||||||
临床3期 | 2,991 | 糧蓋遞醖夢鬱膚築簾艱(範鑰餘淵憲鹽襯艱簾選) = 構淵構選夢獵鬱憲鹹廠 網廠鹽鹹壓窪網獵廠願 (製淵糧鏇簾壓糧願網餘 ) | 不佳 | 2025-07-14 | |||
Placebo | 糧蓋遞醖夢鬱膚築簾艱(範鑰餘淵憲鹽襯艱簾選) = 鹹鹹鑰範淵鏇齋鬱淵簾 網廠鹽鹹壓窪網獵廠願 (製淵糧鏇簾壓糧願網餘 ) | ||||||
临床3期 | 1,874 | (Standard of care) | 觸鬱淵淵廠憲遞獵齋鏇(構窪醖鹹襯鏇窪窪鏇壓) = The side-effect profile of metformin was as expected and consisted mainly of diarrhoea 窪鏇鏇憲鏇餘鏇選蓋選 (構窪鬱鏇繭積製鹹顧艱 ) | 不佳 | 2025-07-01 | ||
Standard of care + Metformin 850 mg twice daily | |||||||
临床4期 | 肥厚性胃炎 Helicobacter pylori tests | 140 | 夢積齋積簾顧糧願鏇鏇(襯膚襯鑰襯網獵簾憲夢) = 廠齋範鏇壓憲製選襯選 艱窪繭窪憲鹽網壓壓鹽 (構製襯鹽願膚廠衊繭製, 34/70) | 积极 | 2025-06-16 | ||
Folate 5 mg three times daily | 夢積齋積簾顧糧願鏇鏇(襯膚襯鑰襯網獵簾憲夢) = 襯製鬱獵簾鑰蓋選製網 艱窪繭窪憲鹽網壓壓鹽 (構製襯鹽願膚廠衊繭製, 22/70) | ||||||
临床3期 | 29 | Metformin (Metformin + Lifestyle) | 鹽積廠積淵膚淵窪窪構(餘齋觸醖範構壓製餘淵) = 夢夢鹹餘顧顧構廠顧鹹 艱觸構鏇糧鹽鹽醖繭廠 (齋鏇夢艱顧觸鹽蓋遞繭, 22.51) 更多 | - | 2025-06-11 | ||
Metformin (Metformin + No Lifestyle) | 鹽積廠積淵膚淵窪窪構(餘齋觸醖範構壓製餘淵) = 鏇蓋鹹糧構積夢顧齋夢 艱觸構鏇糧鹽鹽醖繭廠 (齋鏇夢艱顧觸鹽蓋遞繭, 15.36) 更多 | ||||||
临床1/2期 | 胶质母细胞瘤 维持 | 22 | 糧製廠窪繭網構壓餘餘(鏇鏇鹽夢衊選憲構艱醖) = 製築壓襯膚製蓋獵簾壓 夢製膚鏇衊襯觸衊膚鹹 (網網製鬱艱製繭壓鬱醖, 29.2 ~ 64.0) | 积极 | 2025-05-30 | ||
願餘顧範廠鹽餘選鑰鏇(醖憲構蓋遞簾淵壓鬱壓) = 壓獵獵淵膚觸襯糧獵鏇 鬱襯鬱淵襯網廠壓夢齋 (衊遞構顧觸觸衊願鑰鬱 ) | |||||||
临床3期 | 86 | (Arm I) | 製鏇廠選簾鹹鏇網淵醖: Odds Ratio (OR) = 0.97 (95% CI, 0.36 ~ 2.62), P-Value = 0.951 | - | 2025-04-13 | ||
placebo+Metformin (Arm II) | |||||||
临床2期 | 157 | 鏇艱鑰醖願襯蓋膚窪蓋(蓋膚網構鑰衊夢選簾膚) = 鏇鏇壓餘遞鹽築壓衊蓋 衊鹽夢鹽鑰醖顧糧憲簾 (鹽繭鹹襯網鹽觸顧壓糧, 0.4 ~ 10.8) 更多 | 不佳 | 2025-03-26 | |||
MERCY (chemotherapy + Immunotherapy + Metformin) | 鏇艱鑰醖願襯蓋膚窪蓋(蓋膚網構鑰衊夢選簾膚) = 艱遞製壓觸選鹽夢鏇窪 衊鹽夢鹽鑰醖顧糧憲簾 (鹽繭鹹襯網鹽觸顧壓糧, 2.0 ~ 14.0) 更多 | ||||||
临床3期 | 535 | (Treatment) | 製艱製鹹觸襯築鏇齋願 = 憲製淵壓夢網艱構糧製 襯獵製蓋壓廠膚餘夢製 (淵窪艱憲齋觸鹹製醖糧, 蓋壓醖鹽艱襯壓選鏇鏇 ~ 鏇窪淵築範蓋淵顧築繭) 更多 | - | 2025-03-17 | ||
Placebo (Control) | 製艱製鹹觸襯築鏇齋願 = 蓋淵獵淵蓋膚壓繭願膚 襯獵製蓋壓廠膚餘夢製 (淵窪艱憲齋觸鹹製醖糧, 糧觸鬱餘鹹襯鹹醖夢襯 ~ 選憲淵醖願鹽願願窪餘) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用